Healthcare

Therapeutic Breakthroughs in Alzheimer’s and Parkinson’s Diseases

Disease-Modifying Treatments Likely to Transform the Clinical Management of Alzheimer’s and Parkinson’s Diseases

INDUSTRY
Healthcare

RELEASE DATE
12-Apr-2017
REGION
Global
DELIVERABLE TYPE
Technology Research

RESEARCH CODE
D7B4-01-00-00-00
SKU
HC02790-GL-TR_19884
Yes
SHARE

Therapeutic Breakthroughs in Alzheimer’s and Parkinson’s Diseases
Published on: 12-Apr-2017 | SKU: HC02790-GL-TR_19884

Need more details?

$4,950.00

$3,712.50 save 25 %

DownloadLink
Need more details?

The research service primarily encompasses comprehensive analyses of key emerging therapies across AD and PD.The service includes treatment overviews, emerging therapeutic platforms, IP and funding analysis, and emerging innovation profiles across Alzheimer's and Parkinson's diseases. Furthermore, the research service features the impact of key technology drivers and restraints for the global AD and PD therapeutic industry. The research services also provides an summary of collaborative trends, regional adoption potential, emerging therapeutic platforms and novel growth opportunities across AD and PD.

1.1 Research Scope

1.2 Research Methodology

1.2 Research Methodology (Continued)

1.3 Key Findings

2.1 Alzheimer’s and Parkinson’s Diseases Are Leading Causes of Neurodegenerative Disorders

2.2 Disease-modifying Therapies Likely to Lead Emerging Landscape for AD and PD Management

2.3 Healthcare Burden for AD and PD Likely to Increase in the Future

3.1 Summary of Key Technology Drivers and Restraints

3.2 Technological Advancements Likely to Fuel New Therapeutics for Neurodegenerative Disorders

3.3 Clinical Trial Advancements of Novel Neurological Therapies Limited by High Failure Rates

4.1 Cholinesterase Inhibitors Lead Existing Treatment Platforms for Alzheimer’s Disease

4.2 Disease-modifying Agents Likely to Have High Impact across AD Patients

4.3 US Leads the Patent Landscape for Novel AD Therapies

4.4 Denali Therapeutics Leads the Global Venture Landscape for AD Treatment

4.5 Amyloid Therapies Lead the Emerging AD Treatment Landscape

4.6 Clinical Pipeline Overview for AD

4.7 Small Molecule RIP1 Inhibitor for Treating AD

4.8 Novel Second Generation Tau-aggregation Inhibitor for AD Management

4.9 Immunomodulatory Strategies for Clinical Management of AD

4.10 Targeting Amyloid Aggregates for Clinical Management of Neurodegeneration

5.1 Levadopa Leads the Existing PD Treatment Landscape

5.2 Biologics Pipeline Likely to Garner Increased Focus across the Emerging PD Treatment Landscape

5.3 Emerging Disease-modifying Small Molecules Likely to Lead PD Management

5.4 US Leads the Patent Landscape for Novel PD Therapies

5.5 Significant NIH and Venture Funding Indicative of Growing Focus on PD Therapeutics

5.6 Clinical Pipeline Overview for PD

5.7 Viral Gene Therapy for PD

5.8 Integrated Therapeutic Platform for Neurodegenerative Diseases

5.9 Novel Wearable for Tremor Management

5.10 Targeted Vaccine Platform for PD

6.1 Overview of the Collaborative Landscape

6.2 Developed Economies Likely to Lead Global Adoption Scenario for Neurodegenerative Therapies

6.3 New Symptomatic and Disease-Modifying Treatments for AD and PD on the Horizon

7.1 Growth Opportunity 1: Disease-modifying Therapy

7.2 Growth Opportunity 2: Immunotherapies

7.3 Growth Opportunity 3: Gene Therapies

7.4 Strategic Imperatives for Success and Growth

8.1 Key Contacts

8.1 Key Contacts (Continued)

Legal Disclaimer

9.1 The Frost & Sullivan Story

9.2 Value Proposition: Future of Your Company & Career

9.3 Global Perspective

9.4 Industry Convergence

9.5 360º Research Perspective

9.6 Implementation Excellence

9.7 Our Blue Ocean Strategy


Have questions about this research or need deeper insights?
Speak directly with our analytics experts for tailored recommendations.

Recent related Healthcare research

19 Nov 2026   |   Global   |   Technology Research

Programmable Vaccines: AI-Designed Antigens and Next-Generation Rapid Platforms

Traditional vaccine development is an empirical, time-consuming process that often leads to a high failure rate. With the proven clinical success of RNA vaccines, there has been a focus on accelerating the development of vaccines to address the growing incidence of infectious diseases and emerging p...

17 Nov 2026   |   Global   |   Frost Radar

Frost Radar™: Quantum-Grade Sensor Technology Ecosystem for Healthcare Applications, 2026

Quantum-grade sensors are advancing healthcare by leveraging quantum phenomena to enable highly sensitive, precise, and non-invasive measurements of biological signals and physiological parameters. These innovations enhance diagnostic accuracy, disease monitoring, brain activity measurement, and ear...

16 Nov 2026   |   North America   |   Frost Radar

Frost Radar™: Healthcare Data Interoperability Platforms and Integration Engines in North America, 2026

This Frost Radar™ analyzes the healthcare data platform and integration engine vendors that enable healthcare organization to improve the exchange, utilization, contextualization, and management of clinical, operational, financial, and administrative data. Data issues, AI adoption, and solution gove...

03 Nov 2026   |   North America   |   Market Research

Enterprise Imaging Market, United States, 2025–2030

Enterprise imaging is no longer a technology upgrade. It is becoming the operating model for imaging across the provider organization, and the next investment cycle will decide which vendors lead it. This study gives vendors, ecosystem partners, and provider leaders a 360-degree view of that shift, ...

02 Nov 2026   |   Global   |   Market Research

Continuous Glucose Monitoring Market, Global, 2026

The global continuous glucose monitoring (CGM) market is undergoing a fundamental transformation as the technology evolves from a prescription-led glucose monitoring device into an AI-connected metabolic intelligence ecosystem. Market expansion is increasingly driven by the emergence of over-the-cou...

 

Purchase includes:
  • Report download
  • Growth Dialog™ with our experts

Growth Dialog™

A tailored session with you where we identify the:
  • Strategic Imperatives
  • Growth Opportunities
  • Best Practices
  • Companies to Action

Impacting your company's future growth potential.